The Saxon Bisphosphonate Register - Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws

Oral Oncology

Volumn 48, Issue 4, 2012, Pages 349-354

  Schubert, Marika ^a   Klatte, Ingolf ^b   Linek, Wigbert ^b,e   Müller, Bianca ^c   Döring, Karli ^b   Eckelt, Uwe ^a   Hemprich, Alexander ^c   Berger, Uwe ^d,f   Hendricks, Jörg ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Hospital Chemnitz   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d Professional Association of German Oral and Maxillofacial Surgeons in Saxony ^*  (Germany)

^e NONE   (Germany)

^f Professional Association of German Oral and Maxillofacial Surgeons in Saxony   (Germany)

Author keywords

Bisphosphonate related osteonecrosis; Bisphosphonates; BRONJ; Jaw; Osteonecrosis; Tooth extraction

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; DISEASE REGISTRY; FEMALE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MANDIBLE; POPULATION RESEARCH; PRIORITY JOURNAL; SAXON BISPHOSPHONATE REGISTER; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 84859446214     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.11.004     Document Type: Article

References (40)

1. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonaterelated osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67(5):943-50.
2. Bartl R, Bartl C, Von Tresckow E. Bisphosphonat-Manual. Springer-Verlag; 2005.
3. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws -clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol 2010;186(7):367-73.
4. Fröhlich M. Die Bisphosphonat-Therapie als mögliche Ursache für Kiefernekrosen - Konsequenzen bei der Verordnung. Ärzteblatt Sachsen 2007;84-8.
5. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115(8):1631-7.
6. Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Prevalence ReinschL, et al. Head Face Med 2010;6:11.
7. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44(9):857-69.
8. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.
9. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2008;30(9):1224-30.
10. Lo JC, ÓRyan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68(2):243-53.
11. Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 2010;68(4):797-804.
12. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65(12):2397-410. (Pubitemid 350100982)
13. Curi MM, Cossolin GSI, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonate-related osteonecrosis of the jaws - an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 2011;69(9):2465-72.
14. Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgerytriggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 2011;47(3):191-4.
15. Aguirre JI, Altmann MK, Vanegas SM, Franz SE, Bassit ACF, Wronski TJ. Effects of alendronate on bone healing after tooth extraction in rats. Oral Diseases 2010;16(7):674-85.
16. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010;39(3):251-5.
17. Markose G, Mackenzie FR, Currie WJR, Hislop WS. Bisphosphonate osteonecrosis: a protocol for surgical management. Br J Oral Maxillofac Surg 2009;47(4):294-7.
18. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009;67(9):1904-13.
19. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91. (Pubitemid 351229318)
20. Reich W, Eckert AW, Schubert J. Osteonekrose im Kieferbereich unter Bisphosphonat-Langzeittherapie. Kieferchirurgische und zahnärztliche Sicht. Ärzteblatt Sachsen-Anhalt 2008;14-9.
21. Piesold JU, Al-Nawas B, Grötz KA. Osteonekrose der Kiefer unter Bisphosphonat-Langzeittherapie. Mund Kiefer Gesichtschir 2006;10(5):287-300. (Pubitemid 44425759)
22. Linek W, Döring K. Die Bisphosphonat-assoziierte Kiefererkrankung. Zahnärzteblatt Sachsen, 7+8/10; 32-4.
23. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonaterelated osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009;67(4):850-5.
24. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al. "Bisphossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008;36(2):95-103.
25. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Leitliniengruppe "Septische Chirurgie" der Deutschen Gesellschaft für Mund-, Kiefer und Gesichtschirurgie: Bisphosphonat-assoziierte Kiefernekrosen. 2007. H http://www.awmf.org/uploads/ tx-szleitlinien/007- 091l-S1--Bisphosphonat-assoziierte-Kiefernekrosen.pdf.
26. Deutsch-Oesterreichisch-Schweizerischer Arbeitskreis für Tumoren im Kieferund Gesichtsbereich (DOESAK): Wissenschaftliche Arbeitsgruppe 3 -Bisphosphonate, Datenerhebungsbogen zur strukturierten und multizentrischen Erfassung Bisphosphonat-assoziierter Kiefernekrosen (Basiserfassungsbogen). http://bp-onj-datenbank.de.
27. American Dental Association (ADA) Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006; 137(8): 1144-50.
28. American Association of Endodontists (AAE): AAE Position Statement. Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaws. 2010. http://www.aae.org/uploadedFiles/Publications-and-Research/ Guidelines-and-Position-Statements/bisphosonatesstatement.pdf.
29. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 2010;68(1):107-10.
30. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibtis oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010;28(2):165-75.
31. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66(5):987-94. (Pubitemid 351522818)
32. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(1):46-53.
33. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75.
34. Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol 2011;47(5):420-4.
35. Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intravenous bisphosphonatesrelated osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111(2):153-63.
36. Mücke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 2011;137(5):907-13.
37. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):85-95.
38. Otto S, Hafner S, Grötz KA. The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2009;67(3):589-92.
39. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months followup. Support Care Cancer 2010;18(4):449-60.
40. Pautke C, Bauer F, Bissinger O, Tischer T, Kreutzer K, Steiner T, et al. Tetracycline bone fluorescence. a valuable marker for osteonecrosis characterization and therapy. J Oral Maxillofac Surg 2010;68(1):125-9.